Home › Idiopathic Pulmonary Fibrosis › Illinois › Chicago
Idiopathic Pulmonary Fibrosis clinical trials in Chicago, IL
6 studies for Idiopathic Pulmonary Fibrosis are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
RecruitingPhase 2
- Research Site, Chicago
Pulmonary Fibrosis Foundation Community Registry
RecruitingObservational studyHealthy volunteers welcome
- Pulmonary Fibrosis Foundation, Chicago
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
RecruitingPhase 2
- Rush University Medical Center, Chicago
- University of Chicago Medical Center, Chicago
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
RecruitingPhase 2
- Northwestern Medicine, Chicago
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
RecruitingObservational study
- University of Chicago, Chicago
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
RecruitingObservational studyHealthy volunteers welcome
- University of Chicago, Chicago
Idiopathic Pulmonary Fibrosis trials in other cities
- Birmingham, AL9 studies
- New York City, NY8 studies
- Kansas City, KS7 studies
- Los Angeles, CA7 studies
- Philadelphia, PA7 studies
- Aurora, CO6 studies
- Durham, NC6 studies
- Nashville, TN5 studies
- Dallas, TX5 studies
- Atlanta, GA5 studies
- Charleston, SC5 studies
- Houston, TX5 studies
Other studies in Chicago
- Non-Small Cell Lung Cancer61 studies
- Breast Cancer59 studies
- Cancer (all types)51 studies
- Metastatic Cancer45 studies
- Prostate Cancer45 studies
- Lung Cancer41 studies
- Obesity41 studies
- Ovarian Cancer36 studies
- Colorectal Cancer34 studies
- Stroke34 studies
- Heart Failure31 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.